Melinta Therapeutics, Inc. (NASDAQ:MLNT) reached 64.6% versus a 1-year low price of $0.64. The stock was last seen 4.95% higher, reaching at $1.06 on 01/11/2019. At recent session, the prices were hovering between $0.98 and $1.09. This company shares are 956.6% off its target price of $11.2 and the current market capitalization stands at $56.6M. The recent change has given its price a -43.25% deficit over SMA 50 and -93.82% deficit over its 52-week high. The stock witnessed -24.29% declines, -72.89% declines and -83.69% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found MLNT’s volatility during a week at 11.71% and during a month it has been found around 17.85%.Melinta Therapeutics, Inc. (MLNT) Top Holders
Institutional investors currently hold around $40 million or 71.5% in MLNT stock. Look at its top three institutional owners. Vatera Holdings Llc owns $17.6 million in Melinta Therapeutics, Inc., which represents roughly 31.1% of the company’s market cap and approximately 44.01% of the institutional ownership. Similar statistics are true for the second largest owner, Fmr Llc, which owns 2,874,764 shares of the stock are valued at $3.05 million. The third largest holder is Blackrock Inc., which currently holds $2.57 million worth of this stock and that ownership represents nearly 4.54% of its market capitalization.Melinta Therapeutics, Inc. 13F Filings
At the end of September reporting period, 54 institutional holders increased their position in Melinta Therapeutics, Inc. (NASDAQ:MLNT) by some 5,413,245 shares, 28 decreased positions by 5,969,646 and 19 held positions by 26,485,137. That puts total institutional holdings at 37,868,028 shares, according to SEC filings. The stock grabbed 14 new institutional investments totaling 271,218 shares while 10 institutional investors sold out their entire positions totaling 480,438 shares.Melinta Therapeutics, Inc. (NASDAQ:MLNT) Insider Trades
Multiple company employees have indulged in significant insider trading. Melinta Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Chief Medical Officer Cammarata Sue has acquired 4,000 shares of Melinta Therapeutics, Inc. (MLNT) in trading session dated May. 29, 2018. These shares are worth $20,000 and were traded at $5 each. The SEC filing shows that Vatera Healthcare Partners Llc performed a purchase of 23,257,000 shares. The Director, 10% Owner added these shares by way of transaction on May. 29, 2018. The company’s shares were assimilated at $5 per share worth to an investment of some $116,285,000 on account of Vatera Healthcare Partners Llc.
, Wechsler Daniel Mark, purchased 50,000 common shares of Melinta Therapeutics, Inc. (MLNT) in the open market. In a transaction dated May. 29, 2018, the shares were bought at an average price of $5, giving away a sum of $250,000. After this purchase, 50,000 common shares of MLNT are directly owned by the insider, with total stake valued at $53,000.
In the transaction dated May. 29, 2018, the great number of shares acquired came courtesy the Chief Scientific Officer; Duffy Erin added a total of 4,000 shares at an average price of $5, amounting to approximately $20,000. The insider now directly owns 4,000 shares worth $4,240.Melinta Therapeutics, Inc. (MLNT) Analyst Guide
Several analysts have released their opinion on Melinta Therapeutics, Inc. (NASDAQ:MLNT), with 2 analysts believing it is a strong buy. Whereas 3 of them predict the stock is a hold. Also, there are 2 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2.14 average brokerage recommendation.